A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
ClinicalTrials.gov ID
NCT00464438
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
171Actual
Last Update Posted
Sep 21, 2011Estimated
Start Date
Jun 2007
Primary Completion Date
Sep 2008Actual
Completion Date
Sep 2008Actual
Brief Summary
This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age
Bacterial Conjunctivitis
gatifloxacin
moxifloxacin 0.5% eye drops
Ages Eligible for Study
Child (0-17)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosed with bacterial conjunctivitis
Exclusion Criteria:
chemical or foreign body trauma to either eye
infection in either eye (besides bacterial conjunctivitis)
white spots in the cornea or ulcers in either eye
clinical diagnosis of chlamydia or gonorrhea in either eye